Phase 3 Bladder Cancer Trial, Recruiting NCT06703476 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Bladder Cancer
Back to Bladder Cancer

Phase 3 Bladder Cancer Trial, Recruiting

NCT06703476
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 21 years or older who are scheduled to have a radical cystectomy (surgery to remove the bladder) as a treatment for bladder cancer, performed by a participating surgeon at Memorial Sloan Kettering (MSK)

Who may not be able to join:

  • For the part of the trial involving a medication called alvimopan: people who regularly take opioid pain medications on an ongoing basis are not eligible for that specific part of the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Alvin Goh, MD, Memorial Sloan Kettering Cancer Center

Phone: 646-422-4667

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
21 November 2024
Est. completion
1 November 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Length of hospital stay (Alvimopan); Symptomatic urinary tract infections (Stents)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov